Intense competition and clinical trial failures could be among the headwinds that weigh down the company’s share price in 2017. shares have tumbled over the past year.
Intense competition and clinical trial failures could be among the headwinds that weigh down the company’s share price in 2017. shares have tumbled over the past year.